China National Pharmaceutical Group
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.). Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai) and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
|Founded||November 26, 1998|
|China, exported worldwide|
|Guo Jianxin (Chairman & Party Committee Secretary)|
|Revenue||CN¥247.110 billion (2014)|
|CN¥8.758 billion (2014)|
|CN¥2.705 billion (2014)|
|Total assets||CN¥199.192 billion (2014)|
|Total equity||CN¥31.944 billion (2014)|
|Owner||Chinese central government (100%)|
|Parent||SASAC of the State Council|
|short Chinese name|
|Footnotes / references|
in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.
China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) was founded on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).
BBIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. In late December 2020, it was in Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.
On December 9, the UAE announced interim results from Phase III trials showing BBIBP-CorV had a 86% efficacy against COVID-19 infection. In late December, Sinopharm announced that its internal analysis indicated a 79% efficacy. While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of +90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures. BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19 being developed in Phase III trials.
BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia, Africa, South America, and Europe. Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021. On March 26, Sinopharm said more than 80 million doses had been administered.
- "中国医药集团总公司郭建新职务变动情况" (in Chinese). SASAC of the State Council. 6 May 2014. Retrieved 22 November 2016.
- "管理团队" (in Chinese). Sinopharm. Retrieved 22 November 2016.
- "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
- "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
- "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
- "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
- Reuters Staff (2020-11-19). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Retrieved 2020-12-09.
- "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. Retrieved 2020-12-13.
- Wee, Sui-Lee; Qin, Amy (2020-12-30). "China Approves Covid-19 Vaccine as It Moves to Inoculate Millions". The New York Times. ISSN 0362-4331. Retrieved 2021-02-12.
- "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
- Cohen J (December 2020). "China's vaccine gambit". Science. 370 (6522): 1263–1267. Bibcode:2020Sci...370.1263C. doi:10.1126/science.370.6522.1263. PMID 33303601.
- Tan Y (16 December 2020). "Covid: What do we know about China's coronavirus vaccines?". BBC News. Retrieved 18 December 2020.
- Liu R (2020-12-31). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020-12-31.
- Turak, Natasha (2021-01-18). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021-01-21.
- Dawn.com (2021-02-02). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021-02-03.
- Reuters Staff (2021-01-24). "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. Retrieved 2021-01-24.
- Dumpis, Toms (2021-01-27). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021-01-28.
- "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021-02-18. Retrieved 2021-02-20.
- "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. Retrieved 2021-03-26.
- Aquino, Marco (2021-02-10). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021-02-10.
- "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021-02-28.
- "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". RadioFreeEurope/RadioLiberty. Retrieved 2021-01-21.
- "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021-02-24. Retrieved 2021-02-26.
- "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021-03-15. Retrieved 2021-03-16.
- "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021-02-05. Retrieved 2021-02-28.
- Liu, Roxanne (2021-03-26). "100 million doses of China Sinopharm's COVID-19 vaccines supplied globally". Reuters. Retrieved 2021-03-26.
- Official website
- Official website of China National Pharmaceutical Foreign Trade Corporation
- Official website of China Sinopharm International Corporation
- Official website of China National Pharmaceutical Industry Corporation
- Official website of China National Medical Device Co., Ltd.
- Official website of China National Biotec Group